– USA, TX – AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization, today announced the appointments of Derek Hennecke and Marshall Crew to its Board as independent directors, bringing additional experienced CDMO leadership to drive growth in the complex formulation and manufacturing market.
“We are pleased to welcome Derek and Marshall to the AustinPx Board, bringing proven CDMO expertise that will be invaluable as directors,” said Board Chair, Shaun Kirkpatrick. “The addition of Derek and Marshall, alongside Tim – three founding leaders of commercially successful CDMOs that helped launch the widespread use of amorphous spray drying and other technologies – further demonstrates our commitment to AustinPx’s growth and the realization of the full market potential of KinetiSol Technology, our next generation amorphous dispersion platform.”
About Derek Hennecke
Derek Hennecke currently serves on several boards, he’s a chairman of the board of Microsize and Particle Dynamics and board director of Grand River Aseptic Manufacturing, Inceptor Bio, Kineticos Disruptor Fund, and the Friedreich’s Ataxia Research Alliance. Previously, he was founder and CEO of Xcelience, board director of Oragenics, VP and GM of MDS Pharma Services, and held various leadership roles at DSM Biologics, DSM Anti-Infectives, and Gist-Brocades in the Netherlands, Mexico, and Egypt.
About Dr. Marshall Crew
Dr. Marshall Crew was cofounder and CEO of Agere, a CDMO specializing in spray-dried dispersions and oral bioavailability of poorly soluble molecules that Patheon acquired in 2015. Following Agere’s acquisition, he remained with Patheon as VP of Pharmaceutical Development Services Scientific Excellence, then SVP of Innovation. Following the acquisition of Patheon by Thermo Fisher Scientific, Marshall was appointed group VP and head of the strategy, leading the growth activities for the Pharma Services Group. Dr. Crew currently serves on BioIVT, Formulated Solutions, and Selkirk Pharma boards.
About AustinPx
AustinPx, Pharmaceutics and Manufacturing is a contract development and manufacturing organization providing analytical and formulation development services and cGMP manufacturing for small molecule drugs. We specialize in phase-appropriate development strategies, speed-to-clinic and market strategies, and bioavailability enhancement of poorly soluble molecules – including our next-generation amorphous dispersion platform, KinetiSol Technology.
For more information: https://www.austinpx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
